BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1030 related articles for article (PubMed ID: 23985562)

  • 1. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
    Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
    The NAMS 2020 GSM Position Statement Editorial Panel
    Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction.
    Santoro N; Worsley R; Miller KK; Parish SJ; Davis SR
    J Sex Med; 2016 Mar; 13(3):305-16. PubMed ID: 26944462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing postmenopausal vaginal atrophy. Vaginal dryness is one of the most irritating symptoms of menopause. Here are some ways to relieve it.
    Harv Womens Health Watch; 2010 Mar; 17(7):4-5. PubMed ID: 20480969
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
    Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
    Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Local estrogen therapy--clinical implications--2012 update].
    Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
    Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
    Tan O; Bradshaw K; Carr BR
    Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What should guide our patient management of vulvovaginal atrophy?
    Shapiro M
    Climacteric; 2019 Feb; 22(1):38-43. PubMed ID: 30452294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.
    Kingsberg SA; Larkin L; Krychman M; Parish SJ; Bernick B; Mirkin S
    Menopause; 2019 Feb; 26(2):124-131. PubMed ID: 30130293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
    Kingsberg SA; Wysocki S; Magnus L; Krychman ML
    J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in the world of postmenopausal sex?
    Iglesia CB
    Curr Opin Obstet Gynecol; 2016 Oct; 28(5):449-54. PubMed ID: 27517339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2017 hormone therapy position statement of The North American Menopause Society.
    The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
    Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV; Kagan R
    Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genitourinary menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
    Hocké C; Diaz M; Bernard V; Frantz S; Lambert M; Mathieu C; Grellety-Cherbero M
    Gynecol Obstet Fertil Senol; 2021 May; 49(5):394-413. PubMed ID: 33757926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal estrogen therapy for the treatment of atrophic vaginitis.
    Lynch C
    J Womens Health (Larchmt); 2009 Oct; 18(10):1595-606. PubMed ID: 19788364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.